



Final Appraisal Recommendation

Advice No: 1714 – July 2014

Lipegfilgrastim (Lonquex[®]▼) 6 mg/0.6 ml solution for injection

Submission by TEVA UK Ltd

Recommendation of AWMSG

Lipegfilgrastim (Lonquex[®]▼) is recommended as an option for restricted use within NHS Wales for reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).

Lipegfilgrastim (Lonquex[®]▼) should be restricted for use where a long-acting granulocyte colony-stimulating factor (G-CSF) is appropriate.

Lipegfilgrastim (Lonquex[®]▼) is not recommended for use within NHS Wales outside of this subpopulation.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1297), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	TEVA UK Ltd
Date of first issue	July 2014
Last reviewed	September 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1714:
Lipegfilgrastim (Lonquex[®]▼) 6 mg/0.6 ml solution for injection. July 2014.